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“Sooner or later comes a crisis in our affairs, and how we meet it 
determines our future happiness and success.  Since the beginning 
of time, every form of life has been called upon to meet such 
crisis”    
 -Robert Collier, American motivational author, 1885-1950  
 Our use of technology created a world that can limitlessly distribute news if a 
catastrophic event transpires.  Continental borders no longer obstruct intercultural 
communication. The result of increasing scientific advances leaves no organization impervious 
to both true problems and false rumors spread by the media, public or rivals.  In an instant, an 
issue can erupt and leak into the public domain before a corporation can confer and manage the 
issue internally. Obliteration of a company’s reputation happens in only days, or in some cases 
just a few hours. The improved speed of communication has increased the vulnerability of a 
company being branded as ‘bad’ to the general population.  The pharmaceutical industry is 
especially prone to the occurrence of a crisis because of its growing international operations in 
the healthcare sector. Businesses continue to expand into other world markets, however many 
firms hold on to their distinct national identities. If organizations strongly retain their cultural 
individuality, they may function in different manners.  This can become an issue if a company’s 
values differ from those of the countries in which it operates.  Although a universal set of crisis 
management guidelines is developing because of globalization, businesses still need to be 
sensitive to differing cultural values in other countries. 
 A pharmaceutical is often defined as, any chemical substance used to diagnose, cure, or 
prevent diseases and for restoring, correcting, or modifying organic functions (Geest, & Whyte,  
1996).  Pharmaceuticals are categorized by chemical groups, how they function within the body 
(pharmacological effect), and therapeutic use. Important pharmaceuticals created from natural 
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substances include antibiotics, vaccines, human blood-plasma fractions, and steroid hormones 
(“Drugs,” 2011).   
 From the above definition, one can conclude the manufacturing of medicinal drugs today 
relies heavily on systematic measures, such as manufacturing of the active ingredient and the 
conversion of active drugs into products suitable for administration (Geest, & Whyte, 1996).  
Pharmaceuticals were developed to combat ailments that have cast long shadows over human 
wellbeing.  Throughout the existence of civilization, sickness and disease plagued humanity.  
Medications originated from the knowledge of which plants were effective to fight against a 
sickness.  Today, medications, such as vaccines and antibiotics, are used to prevent illnesses 
from occurring.  The refinement, or process of modifying drugs, diverted onto a more scientific 
route, such as the synthesizing of a medication (Geest, & Whyte, 1996). 
 However, some pharmaceutical companies still produce drugs obtained through natural 
products.  It is important to note the idealistic approach to improve effectiveness and reduce 
harmful side effects of drugs through cutting-edge science is not always reachable.  The 
iatrogenic phenomenon, such as drug side effects, occurs when companies try to develop drugs 
through systematic approaches rather than natural (Farson, 1996). With every new application of 
technology, a counterforce develops which is the exact opposite than what was intended.  Some 
modern medications actually cause more harm than good.  More than a thousand different 
diseases would not exist if not for the practice of medicine such as the use of digoxin, which 
intends to regulate heartbeats, but may cause heart toxicity (Farson, 1996). 
  Today, pharmaceutical corporations are scrutinized more so during a crisis than 
companies in other industries. This is due to the fact that their products affect “the health of 
yourself and your loved ones” (Koster, Politis-Norton, 2004, p. 608).   People usually link crises 
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with the notion of danger and thus often perceive such events in a negative light.  Nonetheless, 
not all recalls are received with the same magnitude of concern.  For example, furniture recalls 
are much less threatening than a drug, with potential adverse side effects.  Issues for drug recalls 
or withdrawals today relate to potency, tampering, dangerous reactions occurring, or lacking 
therapeutic effects (Cheah, Chan, & Chieng, 2007).  Not all drug recalls are necessarily life 
threatening, but those which are receive far more publicity.   
 Regardless of whether or not a firm is international, the organization must comply within 
all laws of the geographical area it operates in.  However, a number of scholars speculate that 
while businesses globalize, many keep their national distinctiveness (Thomas, 2004).  In other 
words, the organization retains its national roots while functioning on a global frontier.  Because 
cultures differ in what they deem as appropriate or responsible, firms respond in different 
management manners to reflect their society’s culture. Nevertheless, a universal area of 
importance for corporate entities in the pharmaceutical industry stresses on immediate action to 
protect consumers. 
 The purpose of this analysis is to examine whether selected pharmaceutical firms in 
Germany, Japan, and the United States operate under a universal set of crisis management 
principles during a disaster situation, or if they are still influenced by the cultures in which they 
originated. At the present, there is no universal journal for ethics in pharmacy.  In other words, 
there is not yet an official set standard of how to operate ethically in the pharmaceutical industry. 
Companies can differ in how they manage a crisis according to social responsibility perceptions 
in the locations they operate in even if it disagrees with other countries (Cheah et al., p. 429, 
2007).  Some countries value the long-term relationships between buyers and sellers, while 
others focus on short-term interactions.  Consequently, how they respond may fluctuate to mirror 
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investors’ or consumers’ expectations. To gain a better understanding of an organizational crisis, 
the definition of a crisis needs to be explored.  In addition, a crisis business model is used to 
determine whether organizations have handled the circumstances in the most productive way to 
save their company’s reputation.  Because businesses in the pharmaceutical industry have unique 
challenges regarding crises, a closer examination of the industries and their regulations must be 
investigated.  For the sole discussion of this paper, the international pharmaceutical companies 
Bayer, Takeda, and Pfizer located in Germany, Japan, and the United States are examined to 
determine whether cultural aspects influence the organization’s management decisions in events 
that can harm their reputation and competiveness.   
Organizational Crisis Defined 
 Organizational crises not only damages the legitimacy of a company, but also harms 
stakeholders and the credibility of the company.  Once a company is perceived pessimistically, 
the reputation and survival of the organization can be in jeopardy.  Consumers may associate the 
firm and/or its products or services negatively, which will tarnish the company’s status.  Usually, 
senior corporate officials will attempt to communicate with the media, and key stakeholders, to 
appear as having controlled or contained the crisis (King, 2002).  While proper management may 
help prevent a crisis, “external factors [still] have a huge influence” (Koster, Politis-Norton, 
2004, p. 604).  For instance, if the amount of news is low or if the organization holds a 
worldwide brand name, usually minimal issues can be amplified and attract a lot of media 
attention to the detriment of the company. 
 An organizational crisis is a vaguely defined concept and often has numerous definitions 
(Snyder et al., 2006).  To this day, scholars struggle to find an adequate, universal definition.   
King (2002) describes a crisis as, “an unplanned event that has the potential of dismantling the 
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internal and external structure of an organization” (p. 237).  Though this definition gives a rather 
generalized explanation of a crisis, it does not elaborate whether the cause of the event was under 
human error, natural disaster, or technology failure.  Depending on the crisis, this distinction can 
make a large difference.  According to Argenti (1998): 
 A crisis is a major catastrophe that may occur either naturally or as a result of human 
 error.  It can include tangible devastation, such as the destruction of lives or assets, or 
 intangible devastation, such as the loss of an organization’s credibility.  In the latter case, 
 the loss of credibility may be the result of management’s response to tangible devastation 
 or the result of human error (p. 214).  
Here the origins of a crisis is better explained, however, the definition does not acknowledge the 
fact that technology now plays a large role in our lives today.  Crises arising from technology 
malfunctions are just as prevalent as those from natural disasters or human mistakes.  
 Over time, the definition of a crisis appears to change in correlation with crisis 
management strategies.  In the past, the organizational crisis classification just touched on what 
causes the event rather than what happens if management does not resolve or assuage the fallout 
after the incident.  A universally accepted term of an organizational crisis is yet to be determined.  
The basic definition for a crisis is covered in each explanation; however, disagreement remains 
when it comes to the specific details of what clearly defines a crisis. 
 Definitions of a crisis appear to vary however, Koster and Politis-Norton (2004) state, 
“the most frequent are wordings which underline the inability of an organisation to have a major 
influence on its course and the speed with which the flow of events escalates during a crisis” (p. 
604).  By analyzing the above definitions, and for the purpose of this paper, a crisis will be 
define as an unexpected, detrimental event caused by natural terms (weather, natural disasters), 
human error, and/or technology failure, harming the reputation as well as the competiveness of a 
company. The incident also negatively affects stakeholders and people external to the 
organization. 
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Crisis Management Business Model 
 Crisis management is a managerial approach that emphasizes preventing crises and 
restoring or minimizing damages caused by an event. A company that responds in a swift, 
generous manner may find itself in a position to strengthen customer loyalty, and improve 
competitive standing; however, if a crisis is not controlled and escalates, the company’s 
reputation maybe under threat.   
 Some widely known corporate crises have developed into international events.  For 
instance, the “TWA’s flight 800, Texaco’s racial discrimination suit, Exxon Valdez, Perrier’s 
benzene problem, Morton-Thiokol’s Challenger explosion, Tylenol’s cyanide-laced pills, Union 
Carbide’s Bhopal tragedy, and Metropolitan Edison’s Three Mile Island disaster,” were not only 
crises in media, but also for the corporations and stakeholders (Argenti, 1998).  Every move the 
company made was in the eyes of a worldwide public.  If the global populace perceives the 
company in a pessimistic light, it can forever tarnish the image of the firm.  Some businesses can 
restore their reputation, but not all are successful.  The scathed image of the company usually 
becomes a liability, which hurts the competitiveness of a firm.  As a result, companies need to 
take preventative steps against any potential damaging event. 
 While it is not feasible to prepare for every accident, a corporation’s responsibility is still 
to prepare for those that may happen to the best of their ability.  Having a plan in place not only 
protects the company’s status, but also those who consume their products.  Crisis management is 
a necessity for every business and needs to be conducted with vigilant care.  Organizations need 
to develop a crisis management plan with the mindset of ‘when’ a crisis would occur rather than 
‘if’ (Koster, Politis-Norton, 2004).   A crisis might not happen in the near future, but in time, 
some destructive event is bound to arise. Corporations need to either take preventative measures 
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or they need to respond proactively at the time of the incident rather than postponing a response.  
Consumers often believe if a company does not act immediately, it is self-serving and does not 
care about the welfare of others. 
 The primary objective of crisis management necessitates on taking the appropriate steps 
to make sure the negative results of a crisis are controlled and limited as much as possible 
(Koster, Politis-Norton, 2004).  According to Koster and Politis-Norton (2004), “Only a handful 
of pharmaceutical companies have learnt from the past of other organisations and their true 
character comes to light during a crisis” (p. 604).  Though each situation differs, many experts 
agree that, “speedy, transparent communication…is more important than ever” (Grewal, & Levy, 
2011, p. 8).  In order to survive a crisis, organizations should be prepared, keep themselves in 
check, respond properly and follow the best practices (Levy, 2011).   
 Many aspects could provoke a crisis, such as, “a product-related disaster, like the under-
reporting of adverse reactions during protocol 321 with trialzolam (Halcion; Upjohn) and the 
cerivastatin (Baycol/Lipobay; Bayer) deaths due to severe rhabdomyloysis” (Koster, Politis-
Norton, 2004, p. 605).  Many, if not all, people take medications.  Pharmaceuticals affect all of 
us.  The jeopardy of one’s health or a loved one’s from a product related disaster often explodes 
into a crisis for all such as in the Merck & Co incident. 
 Merck & Co. is an example of how not to handle a crisis.  In 2004, Merck withdrew an 
arthritis drug, Vioxx, because of evidence the medication increased the chance of heart attacks 
and strokes.  In a study conducted four years prior, Vioxx had already shown an increase in 
cardiovascular problems, but the company did not issue a recall.  The drug maker removed 
Vioxx from markets after serious health incidents increased.   As a result, suddenly consumers 
needed to find new alternatives for arthritis treatment.   Customers were upset because they were 
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left scrambling to find other medications.  Merck’s downfall was they did not immediately 
respond to problems nor initiate any new further in-depth studies, which could have avoided this 
recall (Grewal, & Levy, 2011).   
 On the other hand, the Tylenol cyanide-lacing scare in 1982 illustrates the other end of 
the spectrum.  Top management did not hesitate to withdraw recalled medication and they 
provided the public with transparent communication and information (Adubato, 2008).   Johnson 
and Johnson (J&J), the creators of Tylenol, pulled the medication off store shelves and for the 
time being, stopped product advertising.  Even though J&J was not directly accountable for the 
tampering, they assumed liability.  This action illustrated J&J as accompany who took pride in 
responsible corporate practices.  They exercised good corporate responsibility which did not just 
protect those within the organization, but also consumers.  They restored consumer confidence 
and in doing so reclaimed their position as the leading pain reliever.  Today, the Tylenol incident 
still stands as a golden model for effective crisis management execution.  Recognition of J&J’s 
actions cannot be ignored because people usually concentrate only on mistakes and faults. The 
fact that they are still renowned from the incident shows the degree of respect and approval 
toward J&J’s practices.  They salvaged the corporation’s status by not only enduring the crisis, 
but also regaining their place as a market leader.  J&J has a one-page Credo outlining the firm’s 
obligations to various stakeholders (Grewal, & Levy, 2011).  Several companies have mission 
statements including ethical guidelines or, “emergency response plans in place just in case they 
ever encounter a situation similar to the Tylenol tampering emergency or an industrial accident at 
a manufacturing plant” (Grewal & Levy p. 56, 2011).  By creating these principles, companies 
present themselves as more ethical and socially responsible to consumers. 
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 Below are guidelines recommended by Koster and Politis-Norton (2004) on how to 
prepare an organization for a crisis.  These principles contain similarities to other crisis 
management business models suggested by different experts throughout the global economy.  
Commonalities from several models suggest these proposals are derived from past crisis 
incidents.  The global overlap of guidelines means a universal set of crisis management 
principles is developing.  In general, the models are linked with successful management from 
diverse organizations.   Any corporation will benefit from the suggestions below.  
 Define the real problem as soon as 
possible and solve them quickly 
 Assume the worst 
 Create focus  Consider short-term sacrifice 
 Resist combative instinct  Necessitate clear communication and 
choose an articulate spokesperson  
 
 Define the real problem as soon as possible and solve them quickly 
To effectively manage an issue, those within the organization need to have a clear understanding 
of what exactly is going on, otherwise a proposed solution may only solve one part of a crisis.  
The problem needs to be documented as well; otherwise, it will continue to happen.  If the root 
of the crisis is not identified immediately, valuable time will be wasted on other areas that may 
not be the true origin of an issue.  The longer management or employees postpone defining the 
root of the problem the more chance they take that it could happen again. 
 Create focus 
Internal stakeholders within the organization need to pinpoint the problem and focus on solving 
it, instead of working broadly and trying to cover all aspects.  Identifying the problem also helps 
motivate employees to develop an action plan.  By encouraging others to focus on a positive goal 
instead of an ambiguous fear, they often begin devising a plan for success. 
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 Resist combative instinct 
During a crisis, collaboration within the organization is crucial.  Employees waste more time 
fighting amongst each other than using the energy to help solve the problem.  In addition, 
disputing outside recommendations fogs the company’s focus when the feedback may retain 
significant credibility.  Combative instinct helps no one in the end.  
 Assume the worst 
Prepare for instances where everything that can go wrong does.  A common fault is if a company 
believes nothing will happen or that they absolutely know how to handle every potential 
situation.   For instance, when confronted with a serious crisis, consumer harm damages the 
reputation of a company beyond repair.  When a business accounts for everything that could go 
wrong, they are better prepared to handle the issue from all angles. 
 Consider short-term sacrifice 
In most situations, the long-term survival of an organization greatly outweighs short-term loss.  
The battle to keep revenues may be won, but the war for the company’s survival, lost.  
Preserving a business’s reputation may allow it to rebound from an issue in the future. 
 Necessitate clear communication and choose an articulate spokesperson  
The most important tactic to successful crisis management requires articulate communication. 
Reducing the fallout of a crisis largely depends on how well the company corresponds and how 
the firm responds.   Gene Grabowski, a senior vice president of Washington-based crisis 
communications firm Levick Strategic Communications elaborated, “Ninety-nine percent of 
handling a crisis correctly is communication: who is saying what to whom and what are they 
saying” (Levy, 2011, p. 8).  Communication allows information to flow and gets everybody 
involved on the same page.  It also helps when brainstorm diverse ideas during the planning 
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stage of how to manage a crisis event.  Jim Lukaszewski, president of The Lukaszewski Group 
Inc., a crisis communications division of New Brighton, Minnesota-based Risdall McKinney 
Public Relations, adds that timing of the response is equally important (Levy, 2011, p. 8).   
Regardless of the country, many experts agree communication is the key to effectively handling 
a crisis. Choosing someone who excels in this area will help an organization reach out and 
connect with the public.  On the other hand, sometimes businesses are reluctant to communicate 
for different reasons such as, a desire to avoid panic, fear of legal implications, or not all facts 
are yet available (Koster, & Politis-Norton 2004).  While these issues may justify a company to 
withhold information, under most circumstances non-communication in crisis situations often 
evokes the wrong impression to the public. 
 These principles above reflect the ethical nature and consideration of the needs and 
obligations to an organization’s stakeholders.   Ethical rationality is the morally driven response 
to events (Snyder et al., 2006).  By following these recommendations, an organization protects 
not only itself, but also its consumers and the public.  If a company does not properly prepare, 
they are putting themselves at risk. 
 Pharmaceutical Industry: In-depth Perspectives 
 The pharmaceutical industry develops, manufactures and markets licensed drugs for 
medications.  This industry is subject to laws and regulations regarding the patenting, testing and 
ensuring the safety of marketed drugs.  Debate concerns currently go on regarding whether drug 
regulations should be stricter to ensure patients’ safety (“Pharmaceutical Industry,” 2012).      
 Value in the human physical condition has increased in recent times.  People are finding 
out they can lead a better lifestyle by taking antibiotics and getting the right amount of daily 
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nutritional content.  More consumers purchase medications to ensure a longer, healthier life by 
averting and ameliorating sicknesses. 
 Demand for pharmaceuticals is motivated by the aspiration to cure diseases, prolong 
human life and to satisfy the natural curiosity to obtain knowledge.   Medical researchers and 
scientists alike constantly work on finding new treatments to ailments that plague human life.  
The pharmaceutical industry strives to continuously create effective medicines through new 
scientific knowledge such as synthesizing through a biochemical procedure (“Pharmaceutical 
Industry,” 2012). 
 In order to be profitable, each organization needs to develop and market new medications 
to solve both old and new health problems.  Pharmaceutical companies can create both generic 
and brand medications.  Conventionally, some small businesses produce generic drugs while 
larger organizations leverage their much larger resource bases to drive the innovation of new 
patented medications.   Once a patent expires on the original brand name drug, it can be made 
into a generic.   In order to be considered, the generic drug must have the exact same attributes 
[such as potency and effectiveness], as the brand name product (Synder et al., 2006).  Large 
corporations benefit the most from extensive manufacturing, research, and marketing; while 
smaller corporations compete by specializing in drugs that target one or two particular ailments. 
Generic drugs give small companies a chance to compete successfully within the industry, 
whereas customers benefit by medications at a lower cost ("Industry Profile Biotechnology 
Research Services," 2011).   
 By centering on just a few focus groups, smaller companies utilize their resources to 
concentrate on quality rather than quantity.  Therefore, the motivations of large and small 
businesses differ in the ways of developing and promoting medications.  Nowadays, there is a 
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progressing shift in the operations of the pharmaceutical industry.   For instance, traditional 
pharmaceutical manufacturers are becoming development and marketing companies that obtain 
new drugs from smaller research companies (“Pharmaceutical Industry,” 2012).  Generally, 
larger firms do not focus as much in research and development; instead, they get the new drugs 
from smaller companies and then mass produce pharmaceuticals.  Massive firms stretch broadly 
in their organizational activities, while smaller businesses tend to concentrate on one objective, 
such as the development of new drugs. 
 Through the revolutionary advances of modern medicine, pharmaceutical firms use 
biotechnology to produce new drugs. Biotechnology is a field of applied biology that entails, 
“the use of bioprocesses and living organisms in technology, engineering, medicine and other 
fields requiring bioproducts.  Biotechnology also utilizes these products for manufacturing 
purposes” (Snyder et al., 2006, p. 377).  Rather than relying solely on traditional pharmaceutical 
sciences, such as biochemistry, modern biotechnology utilizes tissue culture technologies [in 
vitro] and genetic engineering (Xia & Buccola, 2005).  More specifically, within medicine, 
applications of biotechnology include gene therapy, genetic testing, drug production, and 
pharmacogenomics (“Pharmaceutical Industry,” 2012). In the past, physicians did not have a 
wide arsenal to combat diseases.  As people discovered the link between pathogens and the 
spread of diseases, pharmaceutical companies started to develop and mass-produce medications 
to ensure the prevention of sickness.  Previous generations did not have the relatively new 
science method of biotechnology and thus, were restricted to develop medications within the 
technology limitations of their time. 
 When using biotechnology, pharmaceutical companies [or biotech firms] have more ways 
to develop medications compared to companies in earlier decades.  Technology allowed for the 
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chemical modifications of natural products to increase strength and potency in drugs. Scientists’ 
desires to find solutions for medical issues influence the demand for this research technique in 
the field of medicine.  Hence, developing medicines now rely on vast knowledge of biotech 
developments.  The modern development of pharmaceuticals involves “gene-splicing to produce 
large quantities of drugs from bacterial fermentation, or the production of monoclonal antibodies 
using mouse or human cells” (Xia & Buccola, 2005, p. 235). For instance, pharmaceutical 
corporations develop new generic biotech drugs, called biosimilars, as an alternative way to 
generate revenues.  Currently, generic biotechs are not allowed in the U.S., but are sold in 
Europe (Marcus, 2011).  The U.S. bars biosimliars because “they were not part of the 1984 
landmark Hatch-Waxman law, which allowed for cheaper generic drugs from chemically derived 
products” (Japsen, 2011 p. 1).   
 Given that biotechnology is another source to create new medicinal treatments, 
pharmaceutical manufacturing increasingly overlaps with the biotechnology industry (Maurer & 
Fischer, 2010).  Analogous features between both markets influence the functions of 
organizations that create medicines using this technique.  This synchronization allows for both 
industries to synergize their research and manufacturing efforts, providing consumers with 
potential high quality products.  Because of the public’s increasing reliance on medications, the 
demand for drugs continues to increase.    
 Annual revenue for the pharmaceutical industry is around $200 billion, thus making the 
market highly lucrative worldwide.  The industry is highly competitive for operating firms due to 
the opportunity to earn so much capital (“Pharmaceutical Industry,” 2012).  The pharmaceutical 
industry became a high profile industry because the potential for generating mass amounts of 
income worldwide.   This high profile stems from the fact that drug recalls or withdrawals may 
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harm consumers’ wellbeing.  Most of all, the pharmaceutical industry is prone to greater crises 
because of its linkage with healthcare. 
 With increasing global awareness of maintaining one’s health, this industry expands 
throughout the world, especially in the U.S.  The entire size of the international pharmaceutical 
market experienced a “6-7% growth in 2006…with the size of the market around U.S. $640-650 
billion (Cheah et al., 2007, p. 427).  Although organizations continue to compete in this industry, 
there are downsides to participating in this market.  For example, investing large amounts of 
money into the development of a drug could prove to be a loss investment if the Food and Drug 
Administration (FDA) recalls it.  Recalls cost millions and gives companies a bad if they 
mismanaged events. 
 The number of pharmaceutical withdrawals and recalls in the U.S.  have generally 
increased since 1998 (Cheah et al., 2007). Some researchers speculate the recalls are due to the 
lacking of major restrictions of easily attainable prescription drugs.  Despite the fact, other 
experts suggest the spike in recalls regarding generic or over-the counter pharmaceuticals are 
thought to be the result of low quality “raw materials, faulty labeling/packaging, and 
contamination” (“Drugs,” 2011).  These arguments, about regulations not being strict enough, 
propose that because of the high demand of pharmaceuticals, companies are rushing to 
manufacture and get their products out to consumers as quickly as possible.  Therefore, 
corporations are not focusing as much on quality as they should.  On the other hand, some 
authorities counter the FDA operates under stricter medication manufacturing guidelines.  The 
tighter procedures do not allow poor performing drugs to pass into the public domain ("Drug 
Recall Surge," 2011). 
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 Some pharmaceuticals, such as Baycol/Lipobay and Tysabri, were too hazardous for 
human use.  Baycol/Lipobay, a cholesterol-lowering drug, was connected to fifty-two deaths and 
Tysabri [a medication for multiple sclerosis] patients developed progressive multifocal 
leukoencephalopathy, a rare brain disease (Young, 2001).  Even though modern biological 
sciences developed the drugs, Baycol/Lipobay and Tysabri were not effective for public use.  
While biotech is a more scientific way to develop pharmaceuticals, it is not yet the key to 
eliminate all dangerous side effects in medicinal drugs.  The Baycol/Tysabri event tail spun into 
a disaster for both consumers and the corporation.  
 Even though risks are not completely eliminated through use of biotech, several 
pharmaceutical companies all over the globe advance in technology at a rapid velocity to keep up 
with consumer demands.  Swift manufacturing to meet consumer demand raises the issue as to 
whether the quality and effects of medications are being downgraded.  As a result, some low 
quality drugs can endanger consumers’ lives ("Drug Recall Surge," 2011).  Is drug quality not 
emphasized enough just so they can be readily placed on store shelves? Doctors and patients 
alike become more concerned in recent years about the effectiveness of medications and the 
possibility patients will remain sick and need further prescriptions (“Drugs,” 2011).  Each drug 
can affect a patient differently, thus pharmaceutical regulations are installed to ensure a 
consumer’s safety. 
Regulators and Product Regulations 
 In order to understand how well a pharmaceutical company managed a crisis, government 
drug regulations need to be examined. Experts conclude that crises tend to trigger moral beliefs 
in a way everyday proceedings do not (Snyder et al., 2006).   A crisis can severely damage the 
reputation of a pharmaceutical company, because the health of oneself and others is so 
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interwoven with a culture’s moral beliefs.   The success of a corporation is usually parallel with 
how well it operated under governmental policies.  Organizations cannot centralize actions solely 
on ethics because they must also abide by a county’s laws.  The three regulatory agencies for the 
countries in this analysis involve the Medicines and Healthcare products Regulatory Agency of 
the U.K., Federal Food and Drug Administration of the U.S. and the Pharmaceuticals and 
Medical Devices Agency of Japan.  Below are major areas of concentrations for each regulatory 
agency based on the information provided on their websites. 
 The Medicines and Healthcare products Regulatory Agency (MHRA) regulate 
medications in the U.K. or other European companies.  The MHRA works with manufactures 
and wholesalers on the most appropriate and timely action required to help solve quality or 
safety concerns when they arise ("How we regulate medicines," 2012).  By law, manufactures 
need to report to the MHRA of any significant defects in both medicines and medical devices.  
According to European regulations, the criteria on which legislation to control human medicines 
includes safety, quality and efficacy.  The MHRA stresses on taking this responsibility upon 
itself to maintain the sometimes difficult balance between safety and effectiveness.  As a result 
of trying to regulate and protect consumers, the MHRA implements a system of inspection and 
testing that continues through the lifetime of the drug ("How we regulate medicines," 2012).  
 From the information, the MHRA operates under strict pharmaceutical regulations 
because once the agency approves a drug for public use, the medication still needs to go under 
rigorous testing throughout its life.  The MHRA may impose such thorough regulations to act 
socially responsible for the protection of consumers.  The recent heightened interest in corporate 
social responsibility in U.K. markets coincides with the MHRA’s goals to act quickly if a 
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product issue arises (Cheah et al., 2007).  In other words, regulators scrutinize pharmaceutical 
companies in order to prevent issues from developing.  
 Conversely, the Federal Food and Drug Administration (FDA), which regulates 
pharmaceuticals in the U.S., does not receive all adverse event reports that occur with a product.  
Many factors influence whether or not an event will be reported, such as the time a product was 
marketed and the publicity about the event.  In addition, reporting adverse event from the point 
of care is voluntary in the U.S. regarding healthcare professionals and consumers.  However, if a 
drug manufacturer receives an adverse event report, it is required to send the report to the FDA 
as specified by regulations ("Guidance Compliance Regulatory Information," 2012).  According 
to this information, drug laws in the U.S. seem to be more lax comparing to the U.K.  The 
emphasis appears to be placed on individual actions, such as consumers reporting about side 
effects rather than a business executing extensive research before the product launches on the 
market. 
 The Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, focuses on three 
key areas of relief services for adverse health effects, product reviews, and post-marketing safety 
procedures.  These areas create the PMDA’s “safety triangle” system, which uniquely 
contributes to public health.  Under this system, the PMDA hopes to commit its duties in line 
with the Japanese philosophy of maintaining a harmonious society ("PMDA," 2011).  The 
PMDA conducts organizational operations under Japanese cultural values of harmony and 
philosophy.  The agency strives to make decisions not only for the benefit of corporations, but 
for society overall.   
 Hofstede’s cultural dimensions model can be used to help explain action deviations.  
Geert Hofstede was an industrial organizational psychologist in the Netherlands.  He compiled 
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international data from IBM plants from 72 countries.  Careful analysis shaped the six 
dimensions of values, such as, power, collectivism, uncertainty avoidance, masculinity, 
long/short term orientation and indulgence (Draguns, 2007).  Hofstede’s research information 
remains important and it has stood the test of time.  Long-term oriented societies, such as Eastern 
cultures, stress the importance of the future. These cultures foster pragmatic values oriented 
towards rewards, including persistence, saving and capacity for adaptation. In contrast, short 
term-oriented societies value more immediate actions related to the past and the present, 
including steadiness and reciprocation (Draguns, 2007). Using just one of these dimensions, for 
instance long-term versus short-term orientation, explains how selected cultures diverge in 
creating and responding to regulations.   
 The most prevalent differences of Hofstede’s dimensions are seen in the U.S. and 
Japanese regulations.  The U.S. ranks very high in individuality (i.e. low in collectivism).  
Therefore, this could be why reporting adverse event from the point of care is voluntary in the 
U.S. regarding healthcare professionals and consumers ("Guidance Compliance Regulatory 
Information," 2012).  Consumers in this sense need to act out and protect themselves 
individually.  In other words, patients enact their own personal responsibility by reporting 
adverse side effects in pharmaceuticals.  Japan on the other hand, illustrates its emphasis on high 
collectivism by stressing on the importance of the “safety triangle” to protect public health 
("PMDA," 2011).    Countries, such as Japan, that rank high on collectivism and long-term 
orientation concentrate on maintaining social harmony by protecting everyone.  Hence, the needs 
of society greatly outweighs the needs of an individual (Hofstede, Hofstede, & Minkov, 2010). 
 On the other hand, the U.K. generally falls in between the U.S. and Japan in regards to 
long/short-term orientation and individualism/collectivism.  The MHRA regulations concentrate 
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on maintaining the difficult balance between safety and effectiveness in drugs.  The MHRA 
implements a system of inspection and testing that continues through the lifetime of the drug in 
order to protect consumers ("Guidance Compliance Regulatory Information," 2012). This 
statement highlights the importance of accounting for future  events by persistently preserving 
long-term patient relationships (Hofstede, Hofstede, & Minkov, 2010).  However, according to 
MHRA website, laws do not go as far as incorporating philosophy into regulations as does Japan, 
nor does it give consumers more freedom and responsibility when reporting adverse side effects 
("Guidance Compliance Regulatory Information," 2012).  As a result, MHRA regulations of the 
U.K. appear to be somewhere between the U.S. and Japan.   
 The regulatory websites of the MHRA, FDA and PMDA presents an overview of the 
agencies, however exact recall classification can be analyzed to give further operational insight 
of the organizations.  Table I. below includes a summary of the pharmaceutical recall 
classifications in Japan, U.K. and the U.S. 
Table I.  Japanese, United Kingdom, and the United States, Drug Recall Classifications 
Classifications Japan (Pharmaceuticals and 
Medical Devices Agency, 
PMDA) 
U.K (Medicines and 
Healthcare Products 
Regulatory Agency, MHRA) 
U.S (Food and Drug 
Administration, FDA) 
Class I Defect causes substantial 
effect on subjects 
The defect presents a life-
threatening or serious risk to 
health 
Class I recalls are for 
dangerous or defective 
products that predictably 
could cause serious health 
problems or death 
Class II Defect raises low possibility 
of life threatening effect or 
serious injury 
The defect may cause 
mistreatment or harm to the 
patient, but it is not life-
threatening or serious 
Class II recalls are for 
products which may cause a 
temporary health problem, or 
pose only a slight threat of a 
serious nature 
Class III Defect causes only minor 
effect on the human body 
The defect is unlikely to cause 
harm to the patient, and the 
recall is carried out for other 
reasons, such as non-
compliance with the marketing 
authorization or specification 
Class III recalls are for 
products that are unlikely to 
cause any adverse health 
reaction, but violate FDA 
labeling or manufacturing 
regulations 
(Source: Cheah et al., 2007 & PMDA website) 
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 From these classifications, Japan and the U.K. appear to have a similar structures to the 
FDA in terms of classes.   Their regulatory agencies collaborate with the FDA, even if they do 
not always reach the same conclusions or consensus (Cheah et al., 2007).  In addition, product 
recall classes in each of these countries are approximately comparable with another, but they are 
not identical.  In general, most appropriately deemed procedures in one culture are accepted in 
another.  For instance, class I recalls, for each of the three countries are the most urgent; 
removing such medications for safety measures outweighs further promotions to improve a 
product’s integrity.   Any disregard of the above classifications would instantaneously explode 
into a crisis. Large corporations within the pharmaceutical industry experienced numerous crises 
over the last ten years and these issues continue to grow (“Pharmaceutical Industry,” 2011).  The 
information collected from the regulatory agencies’ websites foreshadows how the selected 
companies may respond to a crisis. With this information, the specific firms can now be 
analyzed. 
Bayer AG 
 Bayer AG is a chemical and pharmaceutical company founded in Barmen, Germany in 
1863. Its headquarters is located in Leverkusen, North Rhine-Westphalia, Germany. Bayer AG, 
also referred to as Bayer Group, is comprised of 315 operating businesses worldwide.  The 
company, which created aspirin in 1897, makes health care products, pharmaceuticals, specialty 
materials such as plastics and high-performance materials, and agricultural products for crop 
protection and home garden care (Angelmar, 2007). It operates in the U.S. through Bayer 
Corporation. Aside from its line of Bayer aspirin, the company's best-known consumer brands 
include Aleve, Alka-Seltzer, and One-A-Day vitamins. Bayer’s top selling medications include a 
multiple sclerosis treatment, Betaseron and the birth control pill, Yasmin. Although Bayer 
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produces some very effective and profitable products, the firm dealt a crippling reputational blow 
from a statin, or anti-cholesterol medicine, Baycol/Lipobay (Angelmar, 2007).   
 Bayer’s Baycol originally launched in the U.K. in April 1997.  Through several 
partnerships, Baycol entered other markets such as the U.S., France, Italy, Spain and Japan.  The 
U.S. was the focus with over 60% of statin sales. In the U.S., Baycol had a label warning about 
rhabdomyloysis, which is the breakdown of muscle fibers resulting in the release of muscle fiber 
contents into the bloodstream. This often results in kidney damage (Angelmar, 2007).  For a 
time, Bayer managed some seemingly inconsequential issues related to the drug such as adding 
gemfibrozil treatment to the Baycol warning label ("Bayer Corp. Restructuring Assists 
Recovery," 2010). 
  However, in the latter half of 2000, Bayer’s Drug Safety division noticed a significant 
increase in the number of rhabdomyloysis reports associated with Baycol.  Between September 
2000 and February 2001, “eighteen cases of Baycol-associated fatal rhabdomyloysis were 
reported worldwide comparing to eight and two, respectively, for the preceding two six-month 
periods” (Angelmar, 2007, p. 81).  This sudden increase flagged the safety and effectiveness of 
Baycol.  For many, an increase from two cases to eighteen is alarming.  What caused this sudden 
spike?  After the studying reports, Bayer employees noted that the only one of the fatal cases 
involved gemfibrozi a drug, which is prescribed when diets change to assist the reduction of 
cholesterol and triglycerides in the blood of certain people who are at risk of pancreatic disease 
(Alperowicz, & Westervelt 2003). As a result, Bayer requested a change in U.S. prescribing 
information and stopped shipping 0.8mg dosage samples to U.S. doctors (Angelmar, 2007).  A 
lower dosage, of 0.4mg entered the U.S. market, but the 0.8mg dosage soon launched in the U.K.    
Bayer’s response to lower dosage reflects their tentativeness to modify their product.  At first, 
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their response to lower dosage in the U.S. appears to be responsible; however, they should have 
postponed the release of the 0.8mg dosage in the U.K. or at least investigated Baycol more to 
prevent issues in the international market (Alperowicz, & Westervelt 2003). Their lack of further 
research soon deflected any responsible image they acquired from lowering dosages in the U.S. 
Over time, authorities in the U.K. also noted concern about fatal cases of rhabdomyloysis 
associated with Baycol and a push for lower dosages followed suit.  The U.S. maintained the 
highest prescribed amount of 0.4mg while Japan took a stricter approach and only approved 
0.15mg or lower (Angelmar, 2007).  
 On June 15 of 2000, Bayer publically revealed the results of a Bayer commissioned study 
on the relationship between Baycol and myopathy [muscle weakness] ("Bayer Corp. 
Restructuring Assists Recovery," 2010).  Problems regarding myopathy cases eventually could 
interrelate with occurrences of rhabdomyloysis.   Even though Bayer readily revealed the 
outcomes of the research, they had the opportunity to collect the same information earlier in the 
year.  A comparable study was already proposed by Bayer Drug Safety/Epidemiology in March 
2000, however the research was not carried out because an internal stakeholder at Bayer U.S. 
showed no enthusiasm about conducting such an analysis (Angelmar, 2007).  Bayer believed the 
dangers of taking Baycol were not a significant threat to patients and the benefits outweighed the 
overall risks.  However, in reality, confidence in Baycol’s safety deteriorated and concern about 
patients’ wellbeing spread throughout the world. 
 On June 26 of 2000, U.K. officials also restricted the maximum dosage of Baycol to 
0.4mg.  About the same time, Bayer voluntarily suspended the marketing and distribution of the 
0.8mg dosage strength in the U.K.  The deferral only happened two months after Baycol’s launch 
("Bayer Corp. Restructuring Assists Recovery," 2010).  This deferment shows how dangerous 
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Baycol was in reality, even though those within Bayer believe potential issues were not 
statistically great enough to harm many consumers.   Many people disapproved of Bayer’s 
hesitation to inform regulators about possible problems that could arise from taking Baycol 
(Angelmar, 2007).  Although Bayer willingly restricted the circulation of the 0.8mg dosage, 
regulators, such as the FDA, expressed disapproval towards Bayer’s lack of a quick response.  
 During a meeting with Bayer, the FDA presented an analysis of spontaneous reports 
highlighting that, “The crude reporting rates for fatal rhabdomyloysis with Baycol 0.8mg alone 
or in combination with gemfibrozil were in market excess over reporting rages for this event in 
association with certain other marketed statins” (Angelmar, 2007, p. 83).  This accusations 
shows the FDA absolutely did not condone Bayer’s lack of action. Bayer’s inadequacy to 
respond gave the perception they were irresponsible and failed to acknowledge Baycol’s 
shortcomings.  Rather than recognize failures, Bayer primarily dismissed them.    
 In reaction to the external pressures and the growing negative reception of Baycol, Bayer 
attempted to conduct clinical investigations to repair Baycol’s reputation (Angelmar, 2007).  
Rather than focusing on restoring Baycol efficacy, Bayer should have started examining why 
dangerous side effects affected numerous consumers and then do something about it. Gathering 
accurate data from many credible sources could have helped Bayer pinpoint Baycol’s issues at an 
early stage.   Because the data suggested patients were exposed to undue health risks, Bayer 
could begin contemplating Baycol’s withdrawal from markets.   
 In August 2001, Bayer finally concluded the threat of rhabdomyloysis was too great to 
keep Baycol in the market.  They withdrew Baycol from all areas except Japan.  The drug maker 
decided to keep selling Baycol in Japan because gemfibrozil was not available there so the threat 
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of fatal risks seemed minimal.  However, Bayer eventually pulled Baycol from the market in late 
August after the approval of gemfibrozil use in Japan (Angelmar, 2007). 
 The backlash of Baycol’s withdrawal from the market soon scathed all who were 
involved.  Many condemned Bayer’s decision to first notify investors about the possible issues 
with Baycol before regulatory agencies and healthcare professionals.  By prioritizing investors 
before anyone else, people perceived Bayer as more concerned about short-term profits rather 
than health risks that may harm consumers ("Bayer Corp. Restructuring Assists Recovery," 
2010).  The self-serving attitudes of those within Bayer placed a heavy burden on consumers and 
exposed them to the unnecessary and avoidable risks of rhabdomyloysis.  The president of the 
French Medical Association stated, “Bayer decided on the timing of the withdrawal based on 
stock market considerations, without providing prior information to the tens of thousands of 
physicians and pharmacists concerned” (Angelmar, 2007, p. 84).  One must keep in mind 
however that in the U.K., most institutional investors concentrate on long-term perspectives. 
Companies strive to remain on good terms with their investors (Cheah et al., 2007).  
Relationships between corporations and investors need to be maintained over the years. Taking 
this into consideration, Bayer may have been attempting to preserve their relations with investors 
by giving them advanced warnings on the issues that arose.   However, Bayer failed to foresee 
the overall damage Baycol caused them by not considering everyone affected by the withdrawal.  
Bayer focused too narrowly on people directly involved with the company and did not consider 
all stakeholders. These actions made them appear egotistical and unconcerned about customers.  
 Additionally, the German health ministry accused Bayer of not informing the ministry 
soon enough of Baycol/Lipobay’s side effects (Young, 2001).  In the U.K., news of voluntary 
product recalls is the norm because of emphasis on corporate social responsibility.  People 
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expect businesses in the U.K. to take accountability to ensure the maintainability of long-term 
relationships with investors and customers. Shareholders in the U.K. do not differentiate between 
the levels of severity of product recalls or withdrawals when expressing their dissatisfaction of 
product recalls or withdrawals (Cheah et al., 2007).  Consequently, it is surprising Bayer did not 
respond by conducting more research into Baycol side effects and inform regulators 
instantaneously in the U.K., if European cultural norms rewarded firms who quickly act in the 
public’s interest while greatly condemning negligent companies. 
 Bayer also did not appear to have effective crisis management policies that may help 
advert such issues.  For instance, Bayer did have some data suggesting that Baycol usage 
[especially coupled with gemfibrozil] might have been associated with patient fatalities, but they 
did not conduct further tests due to a lack of enthusiasm ("Bayer Corp. Restructuring Assists 
Recovery," 2010).  Rigorous testing should have been conducted, rather than assuming total 
confidence in the drug’s effectiveness and/or that benefits outweighed the risks.  This failure to 
take action resulted to Bayer’s downfall.  After acquiring more information on the dangers of 
taking Baycol, it is reasonably questionable as to why Bayer informed stockholders first before 
patients.  The prioritization of investors downgraded Bayer’s corporate image to profits first, 
patients later.  Even if profit was not their first intention, their lack of action to inform consumers 
makes it appear so. 
  The press described Bayer’s promotional practices as questionable.  Patients became 
overtly apprehensive about the media reports. On average, U.K. industry participants, as well as 
other European markets, emphasize on corporate social responsibility than those in the U.S., and 
Bayer’s reluctance to share information readily, shook consumers’ faith in the pharmaceutical 
industry.  For example, in an opinion poll in Italy, 73% of respondents claimed that, “drug 
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companies deserved criticism and disapproval because they disregard patient safety for profit” 
(Angelmar, 2007, p. 84).  Although some unfavorably perceived companies inevitably fail 
because of their own deceitful practices or ignorance, this still sheds a negative light on other 
pharmaceutical companies who are trying to be ethically responsible. Nevertheless, in the end, 
businesses who take responsibility and swift action are more favorably received in the future 
than those firms who neglect such practices.  Baycol’s forestalling of an immediate response and 
‘irresponsible information provision’ soon hurt them not only reputation wise, but also 
financially (Angelmar, 2007). 
 The impact of Bayer’s withdrawal of Baycol caused a sharp decline in profits.  Within 
just a week, Bayer’s share price dropped from €45 to only €33.  The sharp decline of Bayer’s 
shock was the result of either the direct impact on Bayer’s profits from withdrawing Baycol or 
the cost of litigation, an estimated €10bn (Angelmar, 2007).  Bayer became increasingly plagued 
by lawsuits associated with Baycol.  Bayer’s CEO at the time, Werner Wenning, stated that 
Bayer faced 8,400 lawsuits.  The company claimed to have already paid approximately $150 
million to settle 500 cases out of court (Alperowicz, & Westervelt, 2003).  There is no doubt 
Bayer felt the negative repercussions of Baycol. The numerous lawsuits they were bombarded by 
caused many shareholders to lose confidence in Bayer, thus the slipping share prices.  Product 
recalls and withdrawals placed more systematic risk on the company, which in turn caused stock 
valuation to decrease.  
 The highly publicized Baycol/Lipobay withdrawal produced a shadow of uncertainty on 
the rest of the pharmaceutical industry.  The development of drugs and medical research are 
under scrutiny in recent years.  Many people question whether the efforts to create medicines 
really benefit consumers, or perhaps such companies seek to be the largest profiteer and 
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customers are the ones who suffer the greatest if complications arise (Shah, 2010).  Incidents, 
such as Baycol, further created worried customers and the confidence in pharmaceutical 
products. 
 Although Bayer was pessimistically looked upon due to the Baycol incident, they did 
cooperate with investigations and ultimately changed their tactics.  Their openness to share 
information for investigations appears to be Bayer’s last effort to save its status.  Because of the 
emphasis on corporate social responsibility, Bayer still attempted to preserve their reputation by 
cooperating for the ‘interest of patient health.’  With all the unfavorable ramifications from 
Baycol’s withdrawal, Bayer began to reassess its pharmaceutical strategies (Young, 2001).  Their 
change of strategic thinking and adaption to external responses reflects Bayer’s 
acknowledgement in their failures to maintain consumer confidence.  Bayer recognized errors, 
such as not conducting more follow-up research and not informing regulators about risks sooner, 
could greatly harm the long-term survivability of the company.  In the U.K., as well as the rest of 
Europe, more people focus on long run perspectives (Cheah et al., 2007).  Failure to recognize 
this outlook and conform can eventually destroy the competitiveness of a corporation. 
Takeda Pharmaceutical Company Limited 
 The Japanese pharmaceutical company, Takeda, started back in 1781, when companies 
began selling traditional Japanese and Chinese remedies. Today, Takeda is one of Asia's 
largest pharmaceutical companies.  The company produces branded prescription drugs they sell 
all over the world. Top-selling products include blood pressure treatment Blopress, diabetes drug 
Actos, and ulcer medication Prevacid. Takeda is also a leading maker of over-the-counter 
medications such as cold remedies and vitamins within its home country. In addition, the 
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company markets many products in the U.S. through its subsidiary, Takeda Pharmaceuticals 
North America and Millennium Pharmaceuticals Inc., (Mackenzie, 2012). 
 Historically, most of Takeda's sales came from Japan.  However, in recent years, 
international sales grown to account for about half the company's total revenues, with North 
America as the firm's largest international market. Takeda's growth strategy includes advancing 
its market position in North America by cultivating sales of existing products, Actos and 
Prevacid, as well as promoting recently introduced products Uloric, a drug to help manage uric 
acid levels in patients with gout, and heartburn treatment Dexilant (Mackenzie, 2012).  The 
North American market for Takeda continues to expand along with their innovative new 
products. 
 Millennium Pharmaceuticals Inc., which is owned by Takeda, in collaboration with J&J 
developed the drug Velcade. Drug usage includes treating people with multiple myeloma, a type 
bone marrow cancer and people with mantle cell lymphoma, a fast-growing cancer that begins in 
the cells of the immune system who already tried other medications for these diagnoses.  Velcade 
works by killing cancer cells ("Bortezomib - PubMed Health," 2010). The FDA permitted the 
drug in 2003 as a second-line injection treatment for multiple myeloma. In 2008, the drug was 
approved as a front-line multiple myeloma treatment and as a second-line treatment for mantle 
cell lymphoma.  However, the FDA cautioned patients with liver damage from taking the drug 
because Velcade can increase the risk of liver toxicity and liver damage.   Patients who deal with 
liver problems were recommended to start with a low dose ("Velcade Recall Issued Due to 
Particle Contamination - AboutLawsuits.com," 2010).    Around November of 2010, as a 
precautionary measure, Takeda voluntarily recalled a limited number of lots of Velcade (due to 
the possibility small white polyester particles found in vials. 
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 The U.K. Medicines and Healthcare Products Regulatory Agency first announced the 
Velcade recall after polyester-like particles were found in vials from two different batches. Since 
then, the recall expanded to Japan and the U.S.  Approximately 400,000 vials of the cancer drug 
were recalled worldwide after some contained the particles.  Specifically, the recall affected 
about 195,000 vials distributed in the U.K., 200,000 vials in the U.S. and 22,300 vials sold in 
Japan ("Velcade Recall Issued Due to Particle Contamination - AboutLawsuits.com," 2010).  
The particles themselves may not have been particularly dangerous, but Takeda did not want to 
take the chance. 
  Takeda officials explained the problem was caused by a part of the manufacturing 
process contracted out to a third-party manufacturer. The companies received five complaints of 
the particles seen floating in vials in Europe and Japan after the powder form of the drug was 
reconstituted. However, no reports of particle contamination occurred in the U.S. ("Velcade 
Recall Issued Due to Particle Contamination - AboutLawsuits.com," 2010). The voluntary recall 
made by Takeda and J&J helped prevent patients from potential undesirable side effects because 
of the particles.  Possible contamination results in placing consumers’ wellbeing in jeopardy, 
thus making them sicker rather than healthier.  Promptly recalling the drug eventually limited the 
scope of damage done to Takeda while also stopping more major issues from arising. Therefore, 
notifying consumers about possible contamination helped limit the severity of the impending 
crisis.  The lack of numerous recall data or news articles suggests either the crisis was 
extinguished at the beginning, or perhaps cultural values played a part in the distribution of 
information.    
 For instance, in Japan, where Takeda’s headquarters are located, the press restricts 
negative reports on companies to prevent shaming. Richard Bohr, a Director of Asian Studies at 
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the College of Saint Benedict/Saint John's University in Minnesota and the founding board chair 
of NEO Business College for Women in Tokyo, elaborated that in Japan, the media reports only 
on information companies disclose.  The press does not want to pressure and single out 
corporations, instead they are discrete to promote ‘saving face.’ No respect is the first nail in the 
coffin to a falling out in relationships (R. Bohr, personal communication, February 2, 2012).  
Therefore, as long as no one points out errors to the people responsible, no ‘face’ is lost.  It is 
also considered exceedingly impolite for anyone to bring attention to such mistakes in the 
Japanese culture (De, 1994). 
 Gathering specified information about the Velcade recall proved to be a challenge.  There 
was not a lot of information other than statements that Takeda and J&J simply recalled the 
pharmaceutical.  Although Takeda and J&J collaborated in the development of Velcade, the 
Japanese cultural values of Takeda influences how readily available information is to the public.  
In the Japanese society, leaders, or people who obtain significant power positions, are expected 
to work for the good of citizens.  Collectivism in Eastern societies creates a hieratical nature of 
government and concentrates on society as whole rather than specific individuals (Nisbett, 2003). 
Therefore, collectivism societies try to prevent widespread panic by containing certain 
information.  Nevertheless, what leaders perceive as suitable may not always be in the best 
interest of consumers. For instance, the Japanese government sets the pricing for doctor services.   
However, these regulations poorly compensate Japanese doctors for time spent with patients.  
The institutional norm for doctors consequently evolved into severely minimized patient time.  
As a result, less time interacting with patients reduces the amount of information transferred to 
their patients.  Patients have little knowledge or understanding of product shifts, such as when 
doctors discontinue prescribing older products, therefore consumers have no real opportunity to 
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question medical professionals in the hierarchical medical culture in Japan (Thomas, 2004).  A 
communication breakdown such as this hampers the development of good relations between 
corporations and consumers because misunderstandings can easily occur and escalate into a 
crisis.  Lack of information on the Velcade recall perhaps is the result of companies directly 
controlling the amount of information the public receives.  Many Japanese businesses still stay 
disinclined to release data. 
 For instance, the most recent issue of the Fukushima nuclear crisis in 2011 implies 
Japanese corporations remain reluctant to share information during major crises regardless if 
reports may lead to life threatening consequences to the public.  The nuclear disaster is 
comparable to a pharmaceutical related crisis in a sense because both are sensitive and 
controversial issues.  In other words, mistakes and results can be life threatening.  One can 
conclude from the previous information that Japanese companies do not want people to receive 
news on such adversities (Burrett & Simmons, 2011).  Regardless, people accused Tokyo 
Electric Power Company, or TEPCO, of making “opaque decision-making” and the information, 
which was released insufficiently, addressed citizens’ safety concerns.  The quality and quantity 
of information coming out of Japan created gaping holes in experts’ understanding of the disaster 
(Vartabedian, 2011).  Throughout the Fukushima disaster, a number of experts criticized 
TEPCO’s slow response to requests for information (Burrett & Simmons, 2011).  According to 
Najmedin Meshkati, an USC engineering professor who advised federal agencies on nuclear 
safety issues, "Information sharing has not been in the culture of TEPCO or the Japanese 
government. This issue is larger than one utility and one country. It is an international crisis” 
(Vartabedian, 2011, p. 1).   Because Japanese society retains a hierarchy set of characteristics, 
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they believe sharing sensitive information to inexperienced staff creates more public panic and 
reputation-damaging rumors.   
 In addition, Japanese media also does not want to promote the shaming of a company.  In 
individualistic countries like the U.S., people feel guilt and in collectivistic societies, citizens feel 
shame (Hofstede, Hofstede, & Minkov, 2010). Reporting negative news creates the issue of 
‘losing face’ and hurts not only the reputation of a company, but also employees.  Although 
Japan regulates communication channels, social media and the internet has made it nearly 
impossible for businesses to completely contain such information (Vartabedian, 2011).  In this 
perspective, as long as the amount of outflow of data and reports is controllable by a firm, they 
will do everything they can to keep calamity related information from the public. 
 Contrastingly, the lack of information is possibly because Japanese companies have high 
standards in maintaining product quality and their collaborator J&J already developed enough 
experience about crises through the Tylenol incident.  Insufficient news reports could be the 
result of Takeda and J&J handling the recall swiftly and effectively.  During the 1970s and 
1980s, Japanese products were not of the highest quality.  To construct a better image, the 
Edwards Demings award was created to benchmark and honor high quality products.  The initial 
purpose of this award was to encourage the advancement of quality control activities in Japan 
(The W. Edwards Deming Institute: The W. Edwards Deming Institute, 2012). In recent years, the 
Demings award attracts non-Japanese companies. Rewarding firms’ efforts to improve quality 
encourages others to benchmark their products to receive such a prestigious honor. 
 Additionally, J&J, Takeda’s associate, already experienced how to properly respond in a 
crisis ("Velcade Recall Issued Due to Particle Contamination - AboutLawsuits.com," 2010). By 
quickly recalling Velcade, they did not express any strong intent to push for immediate profits or 
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the costs of withdrawing the drug; instead, they prepared themselves for short-term sacrifices.  
Furthermore, Takeda and J&J readily assumed the worst by assessing the costs of possible 
consumer harm and litigation.  
 Both Takeda and J&J did not believe financial ramifications of the Velcade recall were 
significant.   Takeda’s stock decreased 0.4 percent to 3,955 yen at the 3:00 p.m. close in Tokyo 
trading (Matsuyama, 2010).  The insignificant reduction in stock prices conveys consumer 
confidence in the company.   If shareholders were unsure or disapproved of Takeda’s actions, 
they often sell their shares, which increases supply and thus, cause prices to drop.  However, 
because stock prices did not considerably fall, investors must have decided Takeda’s practices 
did not harm its overall profitability in the near future. 
Pfizer Inc. 
 Pfizer Inc. is a U.S. based corporation in New York City and the world’s largest research-
based pharmaceutical firm.  Pfizer is most recognized for prescription products such as 
cholesterol-lowering Lipitor, pain management drugs Celebrex and Lyrica, pneumonia vaccine 
Prevnar, arthritis drug Enbrel and high blood pressure therapy Norvasc.  Consumer health 
products include leading products as Advil, Centrum, and Robitussin.  Currently, the U.S. is 
Pfizer’s largest market, however, the company retains a strong global presence.  More than half 
of Pfizer’s sales come from international countries (Law, 2011). 
 Bextra is a COX-2 inhibitor or a pain medication, belonging to the same class of 
pharmaceuticals as Vioxx, a drug Merck Co. previously removed from pharmacy shelves after 
safety hazards, such an increase in strokes and heart attacks emerged. Since the late 1990s, 
prescription drugs, such as Bextra, are often used to help alleviate chronic pain conditions like 
arthritis and menstrual cramps. The FDA approved Bextra for public use in November 2001.  
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After the Vioxx recall, the safety of similar drugs came into question, and experts began to 
predict Bextra’s recall ("Bextra Recall - Defective Drug Information," 2012). 
 In November 2004, Pfizer revealed the results of a Bextra cardiovascular study.  The 
study was conducted to calculate the effects of Bextra treatment in pain management for patients 
recovering from coronary artery bypass grafting (McCoy, 2004). An analysis of several studies 
involving 8,000 heart-bypass recipients and arthritis patients showed Bextra doubled heart 
attacks and stroke risks in patients just like its predecessor, Vioxx.  In these studies, patients 
were given either Bextra or a placebo.  The study revealed trial participants treated with Bextra 
were two times more likely to suffer a heart attack, blood clot, stroke, or other adverse 
cardiovascular/thromboembolic event than participants in the control group. Bextra’s risk was 
determined to be marginally higher than Vioxx ("Bextra Lawsuit: Bextra Side Effects, Bextra 
Recall, Drug Information," 2012).  In the studies, the highest risk was seen in patients who had 
bypass operations, signifying that heart patients are particularly vulnerable to the threats.  
  Pfizer’s compliance to share such information demonstrates the company promoted 
transparent communication with the public; however, Pfizer also contradicted themselves by not 
listening to external input.  Transparent communication, such as letting the public know about 
recent findings is a positive action to advert future crises. Experts, and consumers determine for 
themselves whether Bextra was reasonability safe to take or not from the studies conducted.    
Nevertheless, Pfizer refuted the urgings of others to recall Bextra because of the increase in heart 
attacks and strokes.  They insisted that Bextra was still not overtly dangerous in certain areas of 
use and the clinical trial did not adequately warrant a recall ("Bextra Recall - Defective Drug 
Information," 2012). In addition, a Pfizer spokesperson, Joseph Feczko, stated the report created 
“unsubstantiated conclusions” about Bextra’s safety and was also “based on information that has 
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not been published in a medical journal or subject to independent scientific review” (McCoy, 
2004).  Pfizer’s dismissal of the study along with their insistence that no considerable risks 
existed when taking Bextra makes them appear recklessly overconfident that the issues would be 
overlooked.  Although Pfizer provided adequate information to the public, they failed to uphold 
the necessary end for clear communication.   They ignored external responses.    
 Compared to other countries like China or Japan, the U.S. government does not regulate 
the distribution of information as strictly.  The U.S. necessitates the importance of two-way 
communication, which centers on receiving and responding to data.  Western civilizations, such 
as the U.S., accentuate an individual’s right to receive and distribute news; however, the mass 
amount of media one collects may not be accurate or credible (Bell, 2000).   
 As a result, the researcher must take up the responsibility to analyze the information.  On 
the other hand, in Eastern countries, governments tightly regulate news to ensure people hear the 
most precise, or approved information.   Freedom of press is not necessarily an area of concern 
as this ideal ties in with Western individuality rather Eastern interdependence (Bell, 2000).  
Compared to Eastern countries, U.S. citizens believe more so that they have the right obtain data 
for their own personal needs whenever they see fit.  
 If a company conceals vital information from the public and this data is later exposed, the 
firm at fault will be associated with corruption and deceit.  In the U.S., people often perceive 
companies who hid information as unwilling to share data that could amplify their shortcomings.  
As a result, this artificially skews the image of the company positively for the time being, 
however if other information proving otherwise is brought to attention, the efforts to hide 
negative data will backfire.   Companies will either lose competitive advantage or sustain 
damages beyond repair (Marcus, 2011). This may be the reason why Pfizer readily provided the 
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results of their cardiovascular study to the public.  In doing so, consumers can decide for 
themselves whether they should continue taking Bextra, and Pfizer could not be accused of 
concealing important research.  However, a crucial component of two-way communication 
required Pfizer to listen to feedback from the results.  If many requested Pfizer to recall Bextra, 
the company should have known the drug would soon be pulled from store shelves.  A large 
outcry would warrant the recall of the drug regardless of Pfizer’s assurance the drug was still 
safe.  However, the corporation did not listen. 
 After evaluating safety information on a range of ant-inflammatory drugs, the FDA on 
April 7, 2005 requested Pfizer to remove Bextra from the market.  The Bextra recall was ordered 
by the FDA after regulators concluded the potentially fatal risks associated with Bextra far 
outweigh projected benefits ("Bextra Recall - Defective Drug Information," 2012). The FDA 
singled out Bextra because it was determined to give no added benefits as a painkiller or in other 
words, it failed to demonstrate an advantage over other NSAID drugs, which are a family of 
chemicals produced by the cells of the body. These medications treat inflammation, pain, fever 
and support the blood clotting function of platelets ("Nonsteroidal Anti-inflammatory Drugs 
(NSAIDs) - drug class, medical uses, medication side effects, and drug interactions by 
MedicineNet.com," 2012).   
 Bextra was also associated with a deadly skin condition, Stevens Johnson syndrome 
("Bextra Recall - Defective Drug Information," 2012).  Prior to the Bextra recall, Stevens 
Johnson syndrome claimed the lives of some Bextra users.  As a result, Pfizer ceased selling the 
drug both in the U.S. and the U.K.  Bextra safety concerns came to the forefront of social 
awareness after the Vioxx recall in September 2004. Some would argue a Bextra recall has been 
in the making since the FDA first approved this drug in November 2001 ("Bextra Recall - 
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Defective Drug Information," 2012).  Negligence, particularly in the healthcare sector, poses a 
great threat to patients who rely on the effectiveness and safety of a drug (Cheah et al., 2007).  If 
Pfizer knowingly manufactured and distributed Bextra after gathering data on its potentially fatal 
risks, this brings up the issue of unethical behavior and corporate irresponsibility.  Disregard of 
consumer wellbeing created the paradigm that Pfizer had ulterior motives rather than looking out 
for the welfare of customers. 
 Subsequent to the recall, there were numerous lawsuits, with many claiming Pfizer 
deliberately manufactured “this dangerous and defective drug” for years, while negligently 
putting patients' health and lives at risk without proper warning. Many law firms in the U.S. 
encouraged consumers to take action claiming that, “people who have been injured by Bextra 
side effects prior to the Bextra recall have the legal right to seek compensation for their losses 
through a Bextra lawsuit” (Area, 2010, p. 1).  When Pfizer did not push for an immediate Bextra 
recall, many upset consumers felt as though the company’s lack of concentration on customer 
relationships resulted in them not caring about additional health issues that can arise from taking 
the pharmaceutical.  Pfizer’s actions infringed on customers’ belief that they should be informed 
about health risks as soon as they are found.  To implement their individual and legal rights, 
many patients decided to take action and filed for lawsuits against Pfizer (Area, 2010).   
 Several of these lawsuits stated that Pfizer concentrated on shareholder wealth 
maximization by fraudulently promoting Bextra through aggressive marketing.  According to 
these Bextra lawsuits, the ethical line kept moving in the wrong direction during the promotion 
of the drug (Mathews, & Hensley, 2005).  In one lawsuit case, Pfizer was accused of having $50 
bounty paid to representatives when they got doctors to add Bextra to the standard care for 
patients.  The care protocols directed patients to take Bextra in high dosages before operations 
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and afterwards to control pain (Mathews, & Hensley, 2005).  Whether the claim is true or not, 
more Pfizer faced more even more pressure.   They were accused of partaking in deceitful 
practices by not having Bextra come with proper warning labels.  
 The negative publicity of the recall and the growing number of lawsuits contributed to 
Pfizer’s fall in share prices.  Their shares fell to fifty-two cents, or 1.9%, to a close of $27.47 on 
the New York Stock Exchange (Bloomberg, 2010). Bextra received a lot of negative press 
because of the serious circumstances.  This eventually tainted consumers’ trust in pharmaceutical 
companies and those who regulate the industry. 
Summary  
 Bayer’s product Baycol, initially started as a very promising anti-cholesterol medicine, 
however safety issues that arose later on could not be ignored.  Three years after Baycol’s 
successful launch in the marketplace, a spike in rhabdomyloysis reports caused many to question 
the drug’s safety.  As a result, Bayer decided to lower dosages (Angelmar, 2007).  In June of 
2000, Bayer publicized a commissioned study about Baycol’s link with myopathy.  A similar 
study could have been conducted a few years earlier, but was not pursed because of unhinged 
confidence in the effectiveness of Baycol and little interest by internal stakeholders to start a 
study. Nevertheless, the assurance of Baycol’s safety quickly eroded (Angelmar, 2007). 
 As a result, the FDA stepped in and expressed their disapproval on Bayer’s reluctance to 
respond to a growing number of patient health problems. The FDA reported that they thought 
Bayer’s lack of informing regulators as a direct threat to consumer safety (Angelmar, 2007).  
With this perception, Bayer insufficiently provided regulators and consumers enough 
information about the fatal rhabdomyloysis incidents. 
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 The repercussions soon escalated and many condemned Bayer’s futile responses to save 
their company’s reputation.  When Bayer recognized that they need to remove Baycol from the 
market, the company informed investors first rather than regulators.  This move greatly stained 
the corporation’s image because they presented themselves as cold and uncaring to customers 
directly harmed from the drug’s side effects (Cheah et al., 2007).  Patients became increasingly 
worried about cynical media reports on Bayer. Bad public reception led to a blow restricted to 
not only company image, but also financial reports. 
 Declining stock prices and a rising number of lawsuits soon forced Bayer to rethink their 
strategy.  Bayer’s headquarters location in Germany and extensive operations in the U.K., 
amplifies the importance of corporate responsibility operations (Young, 2001).  The 
macroenviromental influences, such as government regulations and consumer preference trends, 
determines the success of a company (Marcus, 2011).  Eventual changes in pharmaceutical 
strategies propose that Bayer acknowledged their communication and indecisive movement 
failures and made new pharmaceutical strategies 
 Although Bayer received a lot of negative press because of Baycol, Takeda’s quick action 
during their crisis helped them avoid going down the same path.  Takeda instantaneously 
recalled Velcade after possible particle contamination occurred in a couple batches of vials.  
They pulled about 400,000 vials of the drug worldwide even though some countries such as the 
U.S. did not report any particle contamination.  Takeda officials claimed that a third-party 
manufacturer was to blame (“Velcade Recall Issue Due to Particle Contamination – 
AboutLawsuits.com,” 2010). 
 After the initial reporting, only sparse amounts of information were available.  The lack 
of reports suggests Takeda stopped issues from escalating because of their concentration on 
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promoting quality benchmarks and protecting consumers.  However, little data illustrates the 
regulation of press in Japanese society, or the company not willing to share information, whether 
for self-profiting or for reducing public panic (Vartabedian, 2011).  Regardless, of real 
intentions, Takeda did not experience a terrible financial impact.  Their stocks did not decrease 
significantly, nor did the public outcry like in the Baycol event. 
 Pfizer on the other hand, experienced the same magnitude of disapproval as Bayer, if not 
more so.  Regulators and consumers alike accused Pfizer of promoting Bextra even though the 
company had information that the drug caused adverse side effects or in some instances, death.  
Despite the urgings of others to recall Bextra because of negative reports, Pfizer disputed 
recommendations.  Pfizer did not listen to feedback from the reports.  As a result, the FDA 
needed to step in and request Pfizer to remove Bextra from the market (“Bextra Recall – 
Defective Drug Information,” 2012).   
 Consumers, who felt they needed to take action, exercised their individual rights.  
Numerous lawsuits plagued Pfizer claiming they carelessly placed patients’ health at risk.  Many 
lawsuits also asserted Pfizer as fraudulently promoting Bextra through aggressive marketing 
rather than doing more research on potential side effects (“Bextra Recall – Defective Drug 
Information,” 2012).  The overwhelming amount of pessimistic publicity took a toll on 
consumers’ and investors’ confidence in Pfizer.  The situation looked bleak, and as a result, 
Pfizer’s stock price considerably lowered along with the public’s ethical expectations in the 
company.  
 Koster and Politis-Norton’s guidelines are a good way to determine if the businesses 
managed crises to the best of their abilities.  Table II. below illustrates in summary how well 
each evaluated business managed a crisis according to the crisis management model guidelines. 
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Table II.  Ratings Based on Crisis Management Guidelines  
Company Guidelines Rating (+ positive, - negative) 
Bayer Define the real problem as soon as possible and solve 
them quickly 
- 
Create focus - 
Resist combative instinct + 
Assume the worst - 
Consider short-term sacrifice - 
Necessitate clear communication and choose an 
articulate spokesperson 
- 
Takeda Define the real problem as soon as possible and solve 
them quickly 
+ 
Create focus + 
Resist combative instinct + 
Assume the worst + 
Consider short-term sacrifice + 
Necessitate clear communication and choose an 
articulate spokesperson 
+/- 
Pfizer Define the real problem as soon as possible and solve 
them quickly 
- 
Create focus - 
Resist combative instinct - 
Assume the worst - 
Consider short-term sacrifice - 
Necessitate clear communication and choose an 
articulate spokesperson 
+/- 
(Based on Koster and Politis-Norton’s crisis management guidelines) 
 In accordance to the crisis management criteria from the model, Takeda operated the best 
and this is supported with the fact that after the Velcade incident, the firm’s stock was not 
significantly impacted.   This could illustrate that investors did not lose faith in Takeda’s 
decisions.  The only possible negative was perhaps Takeda restricted information about the 
incident due to the strict regulations in Japan (De, 1994). 
 The other two businesses, Bayer and Pfizer did not do well in most of the areas, thus 
showing there is a lot of room for improvement. In other words, both firms did not follow the 
crisis management model, resulting in the devaluation of their stock prices and the numerous 
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reports of expert and public disapproval.  However, Pfizer had one +/- rating in common with 
Takeda, which regards transparent communication.   
 Takeda for instance received a positive rating because perhaps the company did report 
everything that was going on to the public as Pfizer also claimed by publishing a study done on 
Bextra.  Where the companies diverged regards their negative ratings.  Takeda may have 
withheld information because of the Japanese cultural influence and the country’s strict 
regulations on information (De, 1994).   Pfizer on the other hand, perhaps knowingly concealed 
negative data on Bextra from the public on their own accord ("Bextra Recall - Defective Drug 
Information," 2012).   
Recommendations  
 In some incidents such as the Enron scandal, employees can clearly discern the company 
committed both illegal and unethical acts, but the answers to all issues are not necessarily black 
and white.   Crises habitually forces change, but do not necessarily make all organizations 
undergo a rigorous self-examination.  Strong resistance is more likely to occur.   As a result, 
some experts argue crises bring out either the best or worst qualities in business (Marcus, 2011).  
Companies are either keen on fixing their shortcomings or resistant to admit failures.   In the 
marketplace, managers are rewarded for quick responses and heavily penalized for any delay.  
Events move swiftly and quickly spin out of control. If a firm is unable to stay ahead of a 
potential disaster as it unfolds, the business often becomes restricted to a reactive mode 
parameter. As a result, oftentimes corporations become victims of circumstances (Watkins & 
Blazerman, 2003). 
 In accord, the best actions these and other pharmaceutical companies need to take require 
both preventative and corrective actions.  It is easier to avoid a crisis than handling one.  
Conceptions of Crisis Management     44 
 
Therefore, improving an organization’s processes to limit causes of undesirable outcomes or 
non-conformities are top priorities.  Preventive actions are employed in response to the 
identification of potential sources of non-conformity ("Quality Systems Approach to 
Pharmaceutical CGMP Regulations," 2012).   
 When managing a crisis, companies should not blindly dispute feedback.  After investing 
so much time and money into the development of a drug, negative news about a medication often 
signifies the potential of a great loss.  However, in order to stop further issues from developing, 
firms must research into it.  Not all information may be credible, but in order to successfully 
discern what feedback is valid and noteworthy, an organization needs to follow up and 
investigate (Koster, & Politis-Norton, 2004).  Pfizer spent so much time trying to dispute 
feedback and build up the efficacy of Bextra, that they could have used their energy to find out 
whether the input justified a recall.  If so, they could have removed the drug from the market 
early on to prevent consumers from further harm, and highlight that their company partakes in 
responsible actions.  If Pfizer critically contemplated feedback, they could have stopped the 
escalation of the issue. 
 Takeda avoided being in the same position as Pfizer altogether.  For instance, they 
quickly recalled contaminated vials even though there was not an eruption of adverse or fatal 
cases.  Takeda did not want to take a chance so they immediately removed the drug from the 
market and stopped the possibility of more problems arising (“Bortezomib – PubMed Health,” 
2010). 
 However, not all corporations can completely avoid every issue, hence the importance of 
companies needing to instantly inform both regulators and consumers about potential issues 
(Koster, & Politis-Norton, 2004). If corporations postpone communicating with the public about 
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issues, people usually condemn them in the future for not prioritizing customers’ well fair. 
Pharmaceutical businesses face two options in a crisis, either to publicize negative information, 
which may be incorrect because more tests need to be conducted, or delay the release and cause 
patients to possibly suffer irreversible harm.  An early release of not thoroughly researched 
information hurts sales and may prevent some patients who could benefit from the product.  
Additionally, if it was a false alarm, the company’s reputation would be harmed and nothing 
gained.  In Bayer’s case, they postponed the release of data too long and many patients suffered 
either fatal or adverse side effects. 
 Bayer is an example of how companies become surmounted under accusations that they 
put short-term profits ahead of patients’ wellbeing.  However, Bayer appeared to learn from their 
mistakes when they decided their strategies needed to be change (“Bayer Corp. Restructuring 
Assists Recovery,” 2010).  Businesses tenaciously refusing to acknowledge their mistakes and 
make no internal reforms are surely doomed to fail in the end. 
 After a crisis arises, corporations must quickly respond with corrective actions.  
Corrective actions are implemented as a response to consumer complaints, undesired levels of 
internal nonconformity, nonconformities identified during an internal audit or unstable trends in 
product and process monitoring ("Quality Systems Approach to Pharmaceutical CGMP 
Regulations," 2012).   Quick responses need to be implemented to acknowledge issues and 
rectify damages.  If corrective actions are instantly executed, the root of the crisis will be 
abruptly cut off before it can grow.  
Conclusion 
 Organizations operating in the pharmaceutical industry are becoming more frequent in 
the globalized economy.  While corporations expand to different consumer bases, they need to be 
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more aware of not only their customers, but also their internal work environment to remain 
competitive (Marcus, 2011).  As companies spread out into other world markets, their decisions 
are influenced by cultural identities spawned in the origin of their headquarters.  Cultural values 
have deep roots within countries.  Changes occur as the countries evolve in modern times, but 
their original beliefs and principles derived from previous generations remain just under the 
surface.   Thus, companies need to be aware of both internal organizational, customer and 
investors’ values. 
 Investors retain the influence to exercise a considerable role in the management of 
corporations.  In previous years, individuals held the most stocks. However, nowadays, 
institutional investors, such as mutual funds and insurance companies, own the majority of 
stocks.  These corporate investors speak with managers of a firm and make suggestions about 
how the business should be operated (Marcus, 2011).  Public reception of Bayer, Takeda and 
Pfizer’s management decisions of their crises were reflected by stock performance after the 
immediate incident.  Therefore, it is vitally important companies pay close attention to the 
culture where they conduct operations, because not all investors uphold the same ideals.  
Although stockholders maintain a strong foothold in company operations, customers are the ones 
who buy the products. 
 Many businesses know consumers retain a vital role in the success of a company.  
Customers are the ones who ultimately demand and purchase a product or service.  Without 
consumer need, products eventually become obsolete. If firms do not adapt, they lose any 
sustainable competitive advantage and flicker away into oblivion.  Business managers must 
handle the needs of customers and their shareholders’ expectations.  In the marketplace, 
corporations are rewarded for taking quick action rather than waiting for the preeminent 
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compromise to emerge (Marcus, 2011).  Mismanaging a crisis usually speeds up the process to a 
company’s demise.   However, corporate entities executing the right actions eventually 
outmaneuver their competition.   
 Responsible corporations set themselves apart from others competing in the same 
industry.  Negative events gives a business publicity.  Even though crises do place companies 
under public scrutiny, this is their chance to show a large audience a whether they care about 
patients or exercise self-serving attitudes.   
 A company must balance the interests of stakeholders.  Concentration can be to work for 
the greater good for the greatest number, a utilitarianism belief, or focusing on social harmony 
and consensus.  Japanese firms have a more balanced view of their responsibilities and the 
groups they serve than European, U.K. or U.S. firms do.  With this mindset, European and U.S. 
companies affirm shareholders as their primary obligation, while Japanese businesses mention 
employees and society before shareholders (Marcus, 2011).  Shareholder influence plays a vital 
role in both Europe and U.S. industries; however, firms failing to recognize the importance of 
customer support must survive the consequences. 
 Preventative and corrective actions are the best crisis management methods Pfizer, 
Takeda, Bayer and any other corporation can execute.  It is easier for firms to avoid crisis than to 
manage them.  However, businesses cannot circumvent all crises therefore; they need to respond 
swiftly in the public’s interest.   To retain a positive company image, firms should promote 
translucent communication with the public and not to indigently refute claims suggesting a drug 
is potentially dangerous (Koster, & Politis-Norton, 2004).  If allegations are indeed correct, 
companies can focus on these issues and promptly withdraw the drug to prevent incurring 
irreversible harm to consumers. 
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 Pfizer for instance, provided the public with information, but when people responded 
negatively to a clinical study, the company dismissed reports as inadequate.  In the U.S., the 
ability to obtain a vast amount of information is the norm (Grewal, & Levy, 2011).  If a company 
conceals results of a study, people automatically assume the entity partakes in deceitful and 
disingenuous actions. For this reason, Pfizer published data on a Bextra cardiovascular study.  
However, when Pfizer dismissed the recommendations to remove Bextra from the market in 
spite of the results, many consumers began to question the drug maker’s motives (“Bextra Recall 
– Defective Drug Information,” 2012).  
 Because Pfizer’s headquarters originated in the U.S., they showed particular sensitivity to 
the needs of shareholders.  One of management’s goals was to satisfy investors.  The company’s 
reluctance to recall Bextra illustrates their concern about negatively affecting shareholders’ trust 
in the business.  The development of drugs demands a large investment on the firm’s behalf and 
creates a massive loss when a medication does not perform as projected.  In the immediate 
aftermath of a recall, shareholders tend to dump their stock as a way to escape quickly from the 
eroding situation (Marcus, 2011). Businesses do everything they can to maintain investors’ 
confidence, but not acknowledging consumers’ or society’s influence usually leads to the firm’s 
downfall like in Pfizer’s case.  
 In contrast to Pfizer’s failure to recall Bextra immediately, Takeda removed Veclade 
from the market before the drug would harm many more consumers (“Velcade Recall Issued Due 
to Particle Contamination – AboutLawsuits.com,” 2010). By this action alone, they prevent any 
potential escalation of the situation.  The Japanese culture emphasizes the importance of 
communication and the ardent affiliation between consumer and businesses; therefore, 
companies in Japan understand the significance of preserving long-term relationships (De, 1994).  
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Takeda expressed concern by responding quickly, even to what seemed like a minor incident of a 
few particles in vials (“Velcade Recall Issued Due to Particle Contamination – 
AboutLawsuits.com,” 2010).   Recalling thousands of batches even though no significant amount 
of adverse threats were found, suggests the company did not want to expose several patients to 
irrevocable harm.   
 Takeda in joint with J&J, took the most responsible route in managing the Velcade crises, 
however their crises arose from external factors or ‘third parties.’ Even J&J’s Tylenol gold 
standard in crisis management resulted from cyanide tampering rather than centralized company 
mistakes (Adubato, 2008).  In contrast, Bayer and Pfizer’s cases were caused by internal faults, 
and they could not transfer the blame to anyone but themselves.  Would Takeda, or even J&J, 
maintain a completely unscathed company image if they handled crises, which came from 
internal mistakes, like Bayer or Pfizer?  On the other hand, would they try to hide the negative 
information or dismiss it to retain the efficacy of their drug that they invested so much capital in?  
This brings up another important question: is it easier to admit you were wrong because of your 
own decisions, or in instances where you relied on the decisions of others?   
 In the Baycol crisis, Bayer had no one to blame, but themselves.  Like in the U.S., 
European firms also conduct operations with shareholders’ interests in mind (Marcus, 2011).  
Nevertheless, European companies do not place as much focus in this area as U.S. businesses do.  
On a scale, Japan would be on one side representing companies that place society over 
shareholders, and U.S. corporate entities on the other [shareholders above society].  U.K. firms 
and other European firms, such as Bayer, operate in the middle.  Consequently, Bayer received a 
large outcry of disapproval when accused of informing shareholders about adverse side effects, 
before patients.  Bayer’s actions were categorized out of the norm in the U.K. because of 
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regulations emphasizing on consumer wellbeing (Cheah et al., 2007).  Nonetheless, Bayer 
recognized their faults and reshaped their strategies.  If businesses cannot avoid a crisis, they 
must learn from the events. 
 While companies continue to function on a global scale, cultural roots and sheer physical 
distances still preserve the distinct national characteristics of societies.  The Bayer, Takeda and 
Pfizer cases suggests firms still manage crises differently due to internal organizational cultural 
values and the external influence of consumer, and investor, expectations.  The potential 
competitive advantage devastation to pharmaceutical companies during a crisis creates the 
incentive to have a general set of guidelines to follow. 
 Even though all corporations throughout the world should operate in accordance to a 
universal set of rules, they still need to adapt these principles to suit the cultural needs of the 
country in which they conduct operations.    Two vital key points exist to help global firms 
succeed and preserve their reputation.  These include, investing energy extensively in 
preventative actions and executing actions that maintains all relationships [either internally or 
externally].  First, preventing a crisis is much easier than handling a disaster burning out of 
control.  Second, societies worldwide do not want to condone corporate psychopathy when a 
corporation's directors do what is best for the company, regardless of the harm created.   People 
within businesses have the ability to think critically and distinguish between right and wrong 
(Achbar et. al., 2004).  Organizations need to serve society rather than exploiting it.  In the long 
run, companies who greatly value their relationships surpass profit driven firms whose image 
becomes tainted with greed and plagued with disaster events.  “Sooner or later comes a crisis in 
our affairs…” but, international corporations appropriately executing rectifying actions to meet 
the needs of cultures, solidify a foundation to ensure their survival and ascendancy in the future. 
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